Tag Archives: Vernon Bernardino

H.C. Wainwright Reaffirms Their Buy Rating on Can-Fite BioPharma (CANF)

In a report released today, Vernon Bernardino from H.C. Wainwright reiterated a Buy rating on Can-Fite BioPharma (CANF – Research Report), with a price target of $5.00. The company’s shares opened today at $1.94. According to TipRanks.com, Bernardino is a

H.C. Wainwright Keeps a Buy Rating on Citius Pharmaceuticals (CTXR)

In a report released today, Vernon Bernardino from H.C. Wainwright reiterated a Buy rating on Citius Pharmaceuticals (CTXR – Research Report), with a price target of $4.00. The company’s shares closed last Friday at $1.38, close to its 52-week high

Aytu BioScience (AYTU) Receives a Buy from H.C. Wainwright

H.C. Wainwright analyst Vernon Bernardino reiterated a Buy rating on Aytu BioScience (AYTU – Research Report) today and set a price target of $3.00. The company’s shares closed last Friday at $1.49. According to TipRanks.com, Bernardino is a 5-star analyst

Aytu BioScience (AYTU) Initiated with a Buy at H.C. Wainwright

In a report released today, Vernon Bernardino from H.C. Wainwright initiated coverage with a Buy rating on Aytu BioScience (AYTU – Research Report) and a price target of $3.00. The company’s shares closed last Thursday at $1.40. According to TipRanks.com,

H.C. Wainwright Remains a Buy on Citius Pharmaceuticals (CTXR)

H.C. Wainwright analyst Vernon Bernardino reiterated a Buy rating on Citius Pharmaceuticals (CTXR – Research Report) today and set a price target of $4.00. The company’s shares closed last Monday at $0.79. According to TipRanks.com, Bernardino is a 5-star analyst

Analysts Offer Insights on Healthcare Companies: Can-Fite BioPharma (NYSE MKT: CANF) and CareDx (NASDAQ: CDNA)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Can-Fite BioPharma (CANF – Research Report) and CareDx (CDNA – Research Report) with bullish sentiments. Can-Fite BioPharma (CANF) H.C. Wainwright analyst Vernon